Biotech stocks are surging. How investors can play the new drug innovation boom

Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.

Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.